Stockscreener 앱 받기
0.935
5.27%
0.0468
Outlook Therapeutics Inc 주식(OTLK)의 최신 뉴스
Real time breakdown of Outlook Therapeutics Inc. stock performanceMarket Activity Summary & Weekly Watchlist for Consistent Profits - Newser
Price action breakdown for Outlook Therapeutics Inc.July 2025 Pullbacks & Verified Momentum Stock Watchlist - Newser
Trend analysis for Outlook Therapeutics Inc. this weekMarket Movement Recap & Expert Approved Momentum Ideas - Newser
Is Outlook Therapeutics Inc. stock trending bullishQuarterly Trade Review & Weekly Watchlist for Consistent Profits - خودرو بانک
Will Outlook Therapeutics Inc. benefit from macro trendsWeekly Stock Report & Daily Volume Surge Trade Alerts - Newser
Technical signs of recovery in Outlook Therapeutics Inc.July 2025 Closing Moves & Weekly Setup with ROI Potential - Newser
Analyzing Outlook Therapeutics Inc. with risk reward ratio chartsRisk Management & Fast Moving Market Watchlists - Newser
Can a trend reversal in Outlook Therapeutics Inc. lead to recoveryJuly 2025 Price Swings & Verified Momentum Stock Watchlist - Newser
Does Outlook Therapeutics Inc. have pricing power2025 Biggest Moves & Low Drawdown Trading Techniques - khodrobank.com
Largest borrow rate increases among liquid names - TipRanks
Is Outlook Therapeutics Inc.’s ROE strong enough2025 Volume Leaders & Technical Buy Zone Confirmation - خودرو بانک
What Fibonacci levels say about Outlook Therapeutics Inc. reboundJuly 2025 Gainers & Expert Approved Momentum Trade Ideas - Newser
Is Outlook Therapeutics Inc. showing insider buyingPortfolio Risk Report & Consistent Profit Alerts - خودرو بانک
How to build a custom watchlist for Outlook Therapeutics Inc.2025 Market Sentiment & Weekly Stock Breakout Alerts - Newser
Outlook Therapeutics shares fall 1.61% intraday after requesting a meeting with the US FDA. - AInvest
Will Outlook Therapeutics Inc. continue its uptrendJuly 2025 Market Mood & Proven Capital Preservation Methods - Newser
Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) - GlobeNewswire
Outlook Therapeutics to Present at EURETINA Innovation Spotlight - AInvest
Will Outlook Therapeutics Inc. benefit from seasonalityOil Prices & Free Verified High Yield Trade Plans - خودرو بانک
Long term hold vs stop loss in Outlook Therapeutics Inc.Market Trend Report & AI Driven Price Forecasts - Newser
Using economic indicators to assess Outlook Therapeutics Inc. potential2025 Breakouts & Breakdowns & Risk Managed Investment Strategies - Newser
Is Outlook Therapeutics Inc. showing signs of accumulationAnalyst Upgrade & AI Based Buy and Sell Signals - Newser
Quantitative breakdown of Outlook Therapeutics Inc. recent moveTrade Signal Summary & Short-Term High Return Strategies - Newser
Tools to assess Outlook Therapeutics Inc.’s risk profileVolume Spike & Community Trade Idea Sharing - Newser
How to track smart money flows in Outlook Therapeutics Inc.July 2025 Sector Moves & Consistent Profit Trade Alerts - Newser
Will Outlook Therapeutics Inc. bounce back from current supportAnalyst Downgrade & Risk Controlled Daily Plans - Newser
Evaluating Outlook Therapeutics Inc. with trendline analysisWeekly Loss Report & Daily Momentum Trading Reports - Newser
Strategies to average down on Outlook Therapeutics Inc.Trade Signal Summary & Consistent Return Strategy Ideas - Newser
Is Outlook Therapeutics Inc. part of any ETF2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - خودرو بانک
Published on: 2025-09-02 23:49:13 - Newser
Is Outlook Therapeutics Inc. meeting your algorithmic filter criteria2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - Newser
US FDA Emphasizes Primary Endpoint Primacy In Vatiquinone, Lytenava CRLs - insights.citeline.com
Outlook Therapeutics provides regulatory update on FDA review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the treatment of wet AMD - Eyes On Eyecare
Outlook Therapeutics receives second FDA CRL over wet AMD BLA - Eyes On Eyecare
Outlook Therapeutics Requests Meeting With US FDA Regarding Complete Response Letter for ONS-5010 - MarketScreener
Outlook Therapeutics’ Path to FDA Clarity and Commercialization of ONS-5010: Strategic and Financial Implications for Biotech Investors - AInvest
Outlook Therapeutics requests Type A meeting with FDA - MarketScreener
Outlook Therapeutics shares rise 1.65% intraday after requesting a Type A meeting with the FDA to discuss ONS-5010. - AInvest
Tools to assess Vanda Pharmaceuticals Inc.’s risk profile2025 Market Outlook & Verified Swing Trading Watchlist - Newser
Outlook Therapeutics Requests Type A Meeting with FDA | OTLK Sto - GuruFocus
Outlook Therapeutics Requests Type A Meeting with FDA - The Manila Times
Outlook Therapeutics Requests Type A Meeting with FDA to Address Complete Response Letter for ONS-5010 Biologics License Application - Quiver Quantitative
Outlook Therapeutics Submits Type A Meeting Request to FDA. - AInvest
FDA Requests Additional Efficacy Data: Outlook Therapeutics Plans Meeting on Wet-AMD Drug ONS-5010 - Stock Titan
Outlook Therapeutics Inc. stock volume spike explained2025 Price Action Summary & Verified Momentum Stock Ideas - Newser
Outlook Therapeutics Reports Q3 Revenue - AOL.com
Wesson Brands Inc. stock outlook for YEAR2025 Biggest Moves & Daily Stock Trend Watchlist - Newser
1.40%
자본화:
|
볼륨(24시간):